heterogeneous nuclear ribonucleoprotein C pseudogene 6Genealiases: []
Q-omics provides the consensus-scored HNRNPCP6 profile across patient tissues and cancer cell-line models. HNRNPCP6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HNRNPCP6 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, HNRNPCP6 RNA expression shows 17,896 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, BRCA, and LSCC as cancer lineages where HNRNPCP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPCP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPCP6 survival associations across molecular data types. HNRNPCP6 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPCP6 RNA expression–survival associations across cancer types. High HNRNPCP6 expression shows unfavorable associations in UVM, ACC, OV and SKCM, but favorable associations in BLCA and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for HNRNPCP6 RNA expression.
This table summarizes HNRNPCP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPCP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPCP6 shows lower tumor expression in KICH and higher tumor expression in BRCA, LUAD, LUSC, COAD and HNSC. The BRCA box plot shows higher HNRNPCP6 RNA expression in tumor versus normal tissue (log2 FC = +0.070, t-test p = .002).
This table shows molecular features associated with HNRNPCP6 in patient tissues and cancer cell lines. In patient samples, HNRNPCP6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
